Evaluation of thymosin α 1 in nonclinical models of the immune-suppressing indications melanoma and sepsis

Expert Opinion on Biological Therapy

Volumn 15, Issue , 2015, Pages 41-49

  King, Robert S ^a   Tuthill, Cynthia ^a  

^a SciClone Pharmaceuticals Inc   (United States)

Author keywords

Anti PD 1; Immunotherapy; Melanoma; Sepsis; Thymalfasin; Thymosin alpha 1

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; CD4 ANTIGEN; COLONY STIMULATING FACTOR 1; CYCLOPHOSPHAMIDE; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; LYMPHOTACTIN; PD 1 ANTIBODY; THYMOSIN ALPHA1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; ANTINEOPLASTIC AGENT; IMMUNOLOGICAL ADJUVANT; IMMUNOSUPPRESSIVE AGENT; THYMOSIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL LOAD; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CECAL LIGATION AND PUNCTURE-INDUCED SEPSIS; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; EVALUATION STUDY; FEMALE; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; LUNG METASTASIS; MELANOMA B16; MONOTHERAPY; MOUSE; NONHUMAN; SURVIVAL RATE; TREATMENT DURATION; TREATMENT INDICATION; TUMOR GROWTH; TUMOR VOLUME; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; DISEASE MODEL; DRUG SCREENING; IMMUNOLOGY; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; PROCEDURES; SECRETION (PROCESS); SEPSIS; SKIN NEOPLASMS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; IMMUNOSUPPRESSIVE AGENTS; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; SEPSIS; SKIN NEOPLASMS; THYMOSIN;

EID: 84957789652     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2015.1008446     Document Type: Article

References (26)

1. Romani L, Bistoni F, Gaziano R, et al. Thymosin alpha 1 activated dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood 2004;103(11):4232-9
2. Romani L, Bistoni F, Perruccio K, et al. Thymosin alpha 1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood 2006;108(7):2265-74
3. Bozza S, Gaziano R, Bonifazi P, et al. Thymosin alpha 1 activates the TLR9/MyD88/IRF7-dependent murine cytomegalovirus sensing for induction of anti-viral responses in vivo. Int Immunol 2007;19(11):1261-70
4. Romani L, Bistoni F, Montagnoli C, et al. Thymosin alpha 1: an endogenous regulator of inflammation, immunity, and tolerance. Ann NY Acad Sci 2007;1112:326-38
5. Garaci E, Favalli C, Pica F, et al. Thymosin alpha 1; from bench to bedside. Ann NY Acad Sci 2007;1112:225-34
6. Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther 2009;9(5):593-608
7. Tuthill C, Rios I, McBeath R. Thymosin alpha 1: past clinical experience and future promise. Ann NY Acad Sci 2010;1194:130-5
8. Wu J, Zhou L, Liu J, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care 2013;17(1):R8
9. Li C, Bo L, Liu Q, et al. Thymosin alpha 1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis. Int J Infect Dis 2014. [Epub ahead of print]
10. Ciancio A, Andreone P, Kaiser S, et al. Thymosin alpha 1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role? J Viral Hepatitis 2012;19(1):52-9
11. Maio M, Mackiewicz A, Testori A, et al. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. J Clin Oncol 2010;28:1780-7
12. Danielli R, Fonsatti E, Calabro L, et al. Thymosin alpha 1 in melanoma: from the clinical trial setting to the daily practice and beyond. Ann NY Acad Sci 2012;1270:8-12
13. Carraro G, Naso A, Montomoli E, et al. Thymosin alpha 1 (Zadaxin) enhances the immunogenicity of an adjuvanted pandemic H1N1v influenza vaccine (Focetria) in hemodialyzed patients: a pilot study. Vaccine 2012;30:1170-80
14. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348:138-50
15. Tucci M, Stucci S, Passarelli A, et al. The immune escape in melanoma: role of the impaired dendritic cell function. Expert Rev Clin Immunol 2014;10(10):1395-404
16. Pierluigi B, D’Angelo C, Fallarino F, et al. Thymosin alpha 1: the regulator of regulators? Ann NY Acad Sci 2010;1194:1-5
17. Romani L, Moretti S, Fallarino F, et al. Jack of all trades: thymosin alpha 1 and its pleiotropy. Ann NY Acad Sci 2012;1269:5-10
18. Pica F, Fraschetti M, Matteucci C, et al. High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma. Anticancer Res 1998;18(5A):3571-8
19. Garaci E, Mastino A, Favalli C. Enhanced immune response and antitumor immunity with combinations of biological response modifiers. Bull NY Acad Med 1989;65(1):111-19
20. Wan J, Shan Y, Shan H, et al. Thymosin alpha 1 promotes the apoptosis of regulatory T cells and survival rate in septic mice. Front Biosci 2011;16:3004-13
21. Xiang XS, Li N, Zhao YZ, et al. Combination therapy with thymosin alpha 1 and dexamethasone helps mice survive sepsis. Inflammation 2014;37(2):402-16
22. Moody T, Badamchian M, Goldstein A. Thymosin alpha 1 prevents lung carcinogenesis. FASEB Journal 1998;12:A1457
23. Moody T, Tuthill C, Badamchian M, Goldstein A. Thymosin alpha 1 inhibits mammary carcinogenesis in Fisher rats. Peptides 2002;23:1011-14
24. Rasi G, Silecchia G, Sinibaldi-Vallebona P, et al. Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. Int J Cancer 1994;57:701-5
25. Routier E, Robert C, Mateus C. Immunotherapies and melanoma. Bull Cancer 2014;101(S2):13-24
26. Philips GK, Atkins M. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Int Immunol 2015;27(1):39-46